Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell

Trial Profile

Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Thrombocytopenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AGRAH003
  • Most Recent Events

    • 13 Jun 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 21 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top